In draft guidance on 2 August, England’s health technology assessment body NICE recommended against National Health Service funding for CSL Behring’s Hemgenix (etranacogene dezaparvovec) to treat adults with moderately severe or severe hemophilia B without a history of factor IX inhibitors, citing uncertainties in both clinical evidence and its cost-effectiveness.
According to NICE, the clinical data uncertainties mean that cost-effectiveness estimates for the gene therapy are also uncertain
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?